MCID: PRG003
MIFTS: 35

Progesterone-Receptor Negative Breast Cancer malady

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Negative Breast Cancer

Aliases & Descriptions for Progesterone-Receptor Negative Breast Cancer:

Name: Progesterone-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060078

Summaries for Progesterone-Receptor Negative Breast Cancer

MalaCards based summary : Progesterone-Receptor Negative Breast Cancer is related to breast cancer and mouth disease. An important gene associated with Progesterone-Receptor Negative Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Proteoglycans in cancer and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are Decreased viability with paclitaxel and cardiovascular system

Related Diseases for Progesterone-Receptor Negative Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Related Disease Score Top Affiliating Genes
1 breast cancer 10.4
2 mouth disease 10.2 ERBB2 PGR
3 glioma 10.2 ERBB2 PGR
4 mucoepidermoid thyroid carcinoma 10.1 ERBB2 PGR
5 histiocytic and dendritic cell cancer 10.1 ERBB2 PGR
6 her2-receptor negative breast cancer 10.1 ERBB2 PGR
7 poliomyelitis 10.1 ERBB2 PGR
8 intestinal neuroendocrine benign tumor 10.1 ERBB2 PGR
9 infiltrating angiolipoma 10.1 ERBB2 PGR
10 central nervous system mature teratoma 10.1 ERBB2 PGR
11 rectal neoplasm 10.1 ERBB2 PGR
12 postpartum depression 10.1 ERBB2 PGR
13 male reproductive organ benign neoplasm 10.1 ERBB2 PGR
14 central nervous system primitive neuroectodermal neoplasm 10.1 ERBB2 PGR
15 polyembryoma of the ovary 10.1 ERBB2 PGR
16 arthus reaction 10.1 ERBB2 PGR
17 fallopian tube carcinosarcoma 10.1 ERBB2 PGR
18 gastrointestinal system cancer 10.1 ERBB2 PGR
19 t-cell adult acute lymphocytic leukemia 10.1 ERBB2 PGR
20 organ system benign neoplasm 10.1 ERBB2 PGR
21 middle ear adenocarcinoma 10.1 EGFR PGR
22 ovarian embryonal carcinoma 10.1 EGFR PGR
23 vulva adenocarcinoma 10.1 ERBB2 PGR
24 her2-receptor positive breast cancer 10.1 ERBB2 PGR
25 pineal region mature teratoma 10.1 EGFR ERBB2
26 breast duct papilloma 10.1 ERBB2 PGR
27 congenital bile acid synthesis defect 10.1 ERBB2 PGR
28 ovarian cystadenocarcinoma 10.1 EGFR ERBB2
29 metagonimiasis 10.1 ERBB2 PGR
30 prostate signet ring cell adenocarcinoma 10.1 EGFR ERBB2
31 spongiotic dermatitis 10.0 EGFR ERBB2
32 vascular hemostatic disease 10.0 EGFR ERBB2
33 pituitary stalk meningioma 10.0 ERBB2 PGR
34 spastic diplegia infantile type 10.0 EGFR ERBB2
35 multinodular goiter 10.0 EGFR ERBB2
36 necrobiosis lipoidica 10.0 ERBB2 PGR
37 lower lip cancer 10.0 EGFR ERBB2
38 mikulicz disease 10.0 ERBB2 TLR4
39 tenosynovitis of foot and ankle 10.0 ERBB2 PGR
40 plague 10.0 EGFR ERBB2
41 skin sarcoma 9.9 EGFR ERBB2 PGR
42 cervical lymphoepithelioma-like carcinoma 9.9 EGFR ERBB2 PGR
43 nervous system hibernoma 9.9 EGFR ERBB2 PGR
44 basaloid squamous cell carcinoma 9.9 EGFR ERBB2 PGR
45 combined t cell and b cell immunodeficiency 9.9 EGFR ERBB2 PGR
46 anomalous left coronary artery from the pulmonary artery 9.9 EGFR ERBB2 PGR
47 reactive arthritis 9.9 EGFR ERBB2 PGR
48 anus adenocarcinoma 9.9 EGFR ERBB2 PGR
49 sclerosing hemangioma 9.9 EGFR ERBB2 PGR
50 retinal disease 9.9 EGFR ERBB2 PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Negative Breast Cancer:



Diseases related to Progesterone-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Progesterone-Receptor Negative Breast Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 EGFR ERBB2 PGR SLC4A7 TLR4
2 cellular MP:0005384 9.77 TLR4 EGFR ERBB2 PGR SLC4A7
3 integument MP:0010771 9.62 EGFR ERBB2 PGR TLR4
4 limbs/digits/tail MP:0005371 9.56 EGFR ERBB2 PGR TLR4
5 muscle MP:0005369 9.55 EGFR ERBB2 PGR SLC4A7 TLR4
6 neoplasm MP:0002006 9.26 EGFR ERBB2 PGR TLR4
7 skeleton MP:0005390 9.02 EGFR ERBB2 PGR SLC4A7 TLR4

Drugs & Therapeutics for Progesterone-Receptor Negative Breast Cancer

Drugs for Progesterone-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
3
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
7
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
8
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
9
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
10
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
11
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
12
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
13
Fluorouracil Approved Phase 4,Phase 3,Phase 2 51-21-8 3385
14
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
15
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
16
Pertuzumab Approved Phase 4,Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
17
Toremifene Approved, Investigational Phase 4,Phase 3 89778-26-7 3005573
18
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
20 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
21 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 4,Phase 2,Phase 3,Phase 1
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Diphosphonates Phase 4,Phase 3,Phase 2
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
31 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
35 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
38 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1
40 triamcinolone acetonide Phase 4,Phase 3,Phase 2
41 Epoetin alfa Phase 4 113427-24-0
42 Hematinics Phase 4,Phase 2,Phase 1
43 Triamcinolone diacetate Phase 4,Phase 3,Phase 2
44 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2
45
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
46
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
47
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
48
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
49
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
50
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 599)
id Name Status NCT ID Phase
1 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
2 Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Completed NCT00237133 Phase 4
3 Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Completed NCT00375752 Phase 4
4 Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00022386 Phase 4
5 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed NCT00127933 Phase 4
6 Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients Recruiting NCT02062489 Phase 4
7 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4
8 Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival Recruiting NCT01574170 Phase 4
9 Pharmacology of Adjuvant Hormonotherapy in Breast Cancer Active, not recruiting NCT01127295 Phase 4
10 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer Active, not recruiting NCT02445586 Phase 4
11 MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Active, not recruiting NCT01501487 Phase 4
12 Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059) Terminated NCT00604968 Phase 4
13 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3
14 Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Unknown status NCT00253422 Phase 3
15 Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer Unknown status NCT00072020 Phase 3
16 A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer Completed NCT00938652 Phase 3
17 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3
18 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3
19 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3
20 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3
21 PROACT - Pre-Operative Arimidex Compared To Tamoxifen Completed NCT00232661 Phase 3
22 Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer Completed NCT00352378 Phase 3
23 Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic Completed NCT00003440 Phase 3
24 A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer Completed NCT00022672 Phase 3
25 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer Completed NCT00545077 Phase 3
26 BIG 02/98 Docetaxel - Breast Cancer Completed NCT00174655 Phase 3
27 A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer Completed NCT00091442 Phase 3
28 PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer Completed NCT00236275 Phase 3
29 Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer Completed NCT00868634 Phase 3
30 Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Completed NCT00944918 Phase 3
31 A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer Completed NCT00950300 Phase 3
32 The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) Completed NCT00266799 Phase 3
33 THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. Completed NCT00448279 Phase 3
34 A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer Completed NCT00929240 Phase 3
35 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) Completed NCT01250379 Phase 3
36 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) Completed NCT01120184 Phase 3
37 Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients Completed NCT01099436 Phase 3
38 Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Completed NCT00567554 Phase 3
39 TBP Study With Capecitabine Plus Minus Trastuzumab Completed NCT00148876 Phase 3
40 Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer Completed NCT00047255 Phase 3
41 Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer Completed NCT00078572 Phase 3
42 A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. Completed NCT00391092 Phase 3
43 A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer Completed NCT01998906 Phase 3
44 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Completed NCT00863655 Phase 3
45 Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer Completed NCT00075270 Phase 3
46 Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer Completed NCT00248170 Phase 3
47 Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer Completed NCT00233610 Phase 3
48 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
49 A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer Recruiting NCT03168880 Phase 3
50 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3

Search NIH Clinical Center for Progesterone-Receptor Negative Breast Cancer

Genetic Tests for Progesterone-Receptor Negative Breast Cancer

Anatomical Context for Progesterone-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Negative Breast Cancer:

39
Breast

Publications for Progesterone-Receptor Negative Breast Cancer

Articles related to Progesterone-Receptor Negative Breast Cancer:

id Title Authors Year
1
Mediation of Racial and Ethnic Disparities in Estrogen/Progesterone Receptor-Negative Breast Cancer by Socioeconomic Position and Reproductive Factors. ( 27076668 )
2016
2
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer. ( 27314854 )
2016
3
Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. ( 26392082 )
2015
4
Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry. ( 24548865 )
2014
5
A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer. ( 25230850 )
2014
6
Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. ( 20647407 )
2010
7
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. ( 16145046 )
2005
8
Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. ( 15041725 )
2004
9
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line. ( 3702420 )
1986

Variations for Progesterone-Receptor Negative Breast Cancer

Expression for Progesterone-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Negative Breast Cancer.

Pathways for Progesterone-Receptor Negative Breast Cancer

Pathways related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1 11.74 EGFR ERBB2 TLR4
2
Show member pathways
11.49 EGFR ERBB2
3
Show member pathways
11.43 EGFR ERBB2 TLR4
4 11.37 EGFR ERBB2
5 11.35 EGFR ERBB2
6 11.31 EGFR ERBB2
7 11.27 EGFR ERBB2
8 11.18 EGFR ERBB2
9
Show member pathways
11.17 EGFR ERBB2 PGR
10 11.06 EGFR ERBB2
11 10.86 EGFR ERBB2
12 10.8 EGFR ERBB2
13 10.79 EGFR ERBB2 TLR4

GO Terms for Progesterone-Receptor Negative Breast Cancer

Cellular components related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.33 EGFR ERBB2 SLC4A7
2 endosome membrane GO:0010008 9.13 EGFR ERBB2 TLR4
3 basolateral plasma membrane GO:0016323 8.8 EGFR ERBB2 SLC4A7

Biological processes related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phosphorylation GO:0046854 9.55 EGFR ERBB2
2 wound healing GO:0042060 9.54 EGFR ERBB2
3 positive regulation of cell growth GO:0030307 9.52 EGFR ERBB2
4 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.51 EGFR ERBB2
5 cellular response to mechanical stimulus GO:0071260 9.49 EGFR TLR4
6 positive regulation of epithelial cell proliferation GO:0050679 9.48 EGFR ERBB2
7 positive regulation of MAP kinase activity GO:0043406 9.46 EGFR ERBB2
8 positive regulation of inflammatory response GO:0050729 9.43 EGFR TLR4
9 cellular response to growth factor stimulus GO:0071363 9.4 EGFR ERBB2
10 cellular response to epidermal growth factor stimulus GO:0071364 9.37 EGFR ERBB2
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.32 EGFR TLR4
12 ERBB2 signaling pathway GO:0038128 9.26 EGFR ERBB2
13 regulation of cell motility GO:2000145 9.16 EGFR ERBB2
14 regulation of ERK1 and ERK2 cascade GO:0070372 8.96 EGFR ERBB2
15 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.32 EGFR ERBB2
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR ERBB2
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 EGFR ERBB2
4 transmembrane signaling receptor activity GO:0004888 9.13 EGFR ERBB2 TLR4
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.62 EGFR ERBB2

Sources for Progesterone-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....